tranexamic acid (Lysteda)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: tranexamic acid
BRAND NAME: Lysteda
DRUG CLASS AND MECHANISM: Tranexamic acid promotes the clotting of blood and thereby reduces bleeding due to heavy menstruation. Tranexamic acid is a man-made amino acid derivative that increases blood clotting by preventing the breakdown of fibrin. Fibrin is a protein and an important component of blood clots. It is broken down by another protein called plasmin. Tranexamic acid blocks the action of plasmin on fibrin and thereby prevents the breakdown of fibrin. This leads to stabilization and preservation of fibrin in blood clots, and this helps reduce bleeding during a heavy menstrual cycle. The FDA approved tranexamic acid in November 2009.
GENERIC AVAILABLE: Yes
PREPARATIONS: Tablets: 650 mg.
STORAGE: Tranexamic acid tablets should be stored between 15 C to 30 C (59 F to 86 F).
PRESCRIBED FOR: Tranexamic acid oral tablets are used for the treatment of heavy menstrual cycles.
DOSING: In females 12 years of age and older, the recommended dose is two 650 mg tablets (1300 mg) by mouth three times a day for a maximum of 5 days during the menstrual cycle. It may be administered without regard to meals. Tablets should be swallowed whole and not chewed or broken.
Safe and effective use of tranexamic acid is not determined in premenarcheal girls or girls under the age of 12.
Concomitant use with tissue plasminogen activators (used to prevent or treat blood clots) can reduce the effectiveness of tranexamic acid.
Concomitant use with Factor IX complex concentrates or anti-inhibitor coagulant concentrates that promote blood clots is not recommended due to the increased risk of blood clots.
PREGNANCY: Tranexamic acid is not approved for use in pregnant women. Moreover, there no adequate studies of tranexamic acid to determine safe and effective use in pregnant women.
NURSING MOTHERS: Tranexamic acid is present in breast milk in trace amounts; therefore, caution must be exercised before considering itsuse in nursing mothers.
SIDE EFFECTS: Side effects of tranexamic acid are abdominal and back pain, anemia, joint pain, muscle cramps and spasms, musculoskeletal pain, headache, migraine, nasal and sinus problems, and fatigue. Tranexamic acid may increase the risk of forming blood clots.
REFERENCE: Lysteda – Prescribing Information.
Medically Reviewed by a Doctor on 5/16/2014
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index